Cuban vaccine Abdala has high efficacy rate in serious COVID-19 patients

Cuban vaccine Abdala has high efficacy rate in serious COVID-19 patients
Fecha de publicación: 
22 September 2021
Imagen principal: 

Havana, September 22 (RHC/Prensa Latina) The Center for Genetic Engineering and Biotechnology (CIGB) reported that its Abdala Covid-19 vaccine has an efficacy rate of 90% in seriously ill patients affected by the SARS-CoV-2 virus, according to local media.

The daily newspaper Granma, reported that in July the vaccine was granted authorization for emergency use, after demonstrating 92.28% efficacy in preventing symptoms of the disease.

The latest achievement by the CIGB comes as the aggressive Delta variant of the SARS-COV-2 virus continues to spread on the island. 

'Efficacy should not be confused with effectiveness, since the former is determined in controlled clinical trials, that is, under ideal research conditions; while effectiveness relates to how well the vaccine works in real life, clarified CIGB Director General, Marta Ayala.

Scientists from the CIGB and the Finlay Vaccine Institute - which developed the Soberana 02 and Soberana Plus jabs - recently presented their research, process and development results to the World Health Organization in hopes that the body will approve the vaccines for international use.

Add new comment

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.